BiotechTube
Glaukos

Glaukos

GKOS
United States

Glaukos Corporation (NASDAQ: GKOS) is transforming the treatment of chronic eye diseases through innovative medical devices and pharmaceutical solutions. The company has built a comprehensive portfolio spanning three key ophthalmic areas: glaucoma (featuring the market-leading iStent family), corneal health (including the iLink cross-linking system for keratoconus), and retinal disease drug delivery platforms. With over 300 peer-reviewed publications supporting their MIGS technology and reinvesting approximately 30% of sales into R&D, Glaukos continues to pioneer novel therapies that advance standards of care for millions of patients worldwide.

glaukos.com

GKOS · Stock Price

USD 105.23+2.10 (+2.04%)
Market Cap: $6.3B

Historical price data

AI Company Overview

Glaukos Corporation (NASDAQ: GKOS) is transforming the treatment of chronic eye diseases through innovative medical devices and pharmaceutical solutions. The company has built a comprehensive portfolio spanning three key ophthalmic areas: glaucoma (featuring the market-leading iStent family), corneal health (including the iLink cross-linking system for keratoconus), and retinal disease drug delivery platforms. With over 300 peer-reviewed publications supporting their MIGS technology and reinvesting approximately 30% of sales into R&D, Glaukos continues to pioneer novel therapies that advance standards of care for millions of patients worldwide.

OphthalmologyGlaucomaCorneal DisordersRetinal Diseases

Technology Platform

Micro-invasive surgical devices and drug delivery systems for ophthalmic diseases, featuring trabecular micro-bypass stents, corneal cross-linking systems, and sustained-release platforms for retinal drug delivery.

Pipeline

29
29 drugs in pipeline12 in Phase 3
DrugIndicationStageWatch
TravoprostOpen-angle GlaucomaApproved
TravoprostOpen-angle GlaucomaApproved
Riboflavin 5'-PhosphateKeratoconusApproved
latanoprost/timololEye DiseasesApproved
iDose TR (Travoprost intracameral Implant) 75mcgOpen Angle GlaucomaApproved

FDA Approved Drugs

4
EPIOXA HD/EPIOXA KITNDAOct 17, 2025
IDOSE TRNDADec 13, 2023
PHOTREXA VISCOUS IN DEXTRAN 20%NDAApr 15, 2016

Opportunities

Significant growth opportunities exist in expanding MIGS adoption globally, growing the corneal cross-linking market, and developing breakthrough retinal drug delivery platforms.
The company's strong clinical evidence base and established commercial infrastructure position it well for market expansion.

Risk Factors

Key risks include increasing competition in the MIGS space from larger ophthalmic companies, potential reimbursement challenges, and execution risks in developing retinal drug delivery programs.
Market saturation in core glaucoma segments could also limit future growth rates.

Competitive Landscape

Glaukos leads the MIGS market with the most comprehensive clinical evidence base and established product portfolio, competing against Alcon, New World Medical, and Sight Sciences. The company's first-mover advantage, extensive surgeon training programs, and proven long-term outcomes provide significant competitive differentiation in the ophthalmic device market.